[Countermeasure against infections in malignant diseases].
Ogura
T
T
Third Dept. Int. Med., Univ. of Tokushima School of Med.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001424:Bacterial Infections / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007970:Leukopenia / Q000150:complications; D009181:Mycoses / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D009369:Neoplasms / Q000150:complications* / Q000276:immunology; D005719:gamma-Globulins / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D005719:gamma-Globulins